 |
 | |
 |  |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
Have been following this for some time...story getting more and more interesting...stock trades around .70 on otc bb...high risk...friday's story at bottom: (COMTEX) B: VITRO DIAGNOSTICS INC - Files Landmark Patent for Fertili B: VITRO DIAGNOSTICS INC - Files Landmark Patent for Fertility Drug New York, New York, Mar 26, 2001 (Market News Publishing via COMTEX) -- Vitro Diagnostics, Inc. announced that it has filed a patent application with the United States Patent and Trademark Office entitled "Variant Forms of Human FSH." Vitro's patent filing provides for unique FSH drug therapy specifically directed toward the reduction of multiple births, a major adverse effect of present therapies. The well-publicized birth of septuplets to the McCoughey family in 1997 is an example of the type of unplanned event that Vitro's technology is designed to help control. For the first time in the past 30 years, Vitro's technology may result in new and innovative FSH drugs to lead the treatment of infertility into the 21st century. In addition to reduction of multiple births, Vitro's new FSH products may reduce ovarian hyper-stimulation, a rare but serious side effect of current fertility drugs. Vitro's new invention may also reduce the requirement for daily injections of fertility drugs, which is presently needed for one to two weeks to be effective. The Company's product pipeline includes various forms of purified FSH and related products for use in the treatment of infertility. A plan for the approval of its first product, VITROPIN(TM), is under review by the FDA. VITROPIN(TM) is a highly purified form of urinary FSH produced through the Company's patented method. Additional patent-pending products include VITROPIN-C(TM), custom FSH that reduces side effects of current products, VITROPIN-V(TM), a breakthrough FSH product produced from a proprietary immortalized cell line, and VITROJECT(TM), a novel drug injection device for administration of FSH and other drugs. The new patent filing is related to VITROPIN-C technology and includes methods of production, composition and uses of these novel forms of human FSH. The Company presently has one patent issued in the United States (#5,990,288) concerning processes to purify human and animal FSH. In addition, the Company has another five pending patent applications, which if issued, would provide broad patent protection for the Company's pipeline of products to treat human infertility. Additional information may be accessed through the Company's web site at vitrodiag.com. Certain statements contained herein, which are not historical, constitute "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements are identified by words such as "intends," "anticipates," "believes," "expects" and "hopes" and include, without limitation, statements regarding the Company's plan of business operations, development of products or technologies, receipt of revenues, future financings and completion of certain transactions. Factors that could cause actual results to differ materially include, among others set forth in the Form 10-KSB under the caption "Risk Factors," the following: availability of necessary capital to develop its products, acceptability of the Company's product in the market place, general economic conditions, competition and decisions of third parties over which the Company has no control. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward looking statements, whether as a result of new information, future events or otherwise. MarketbyFax(tm) - To get the NEWS as it happens, call (604) 689-3041. (C) 2001 Market News Publishing Inc. -0- KEYWORD: New York, New York *** end of story *** Vitro Scientists To Present Details of Discovery of New Method To Grow Human Cells for Drug Production and Other Uses LITTLETON, Colo., May 4 /PRNewswire/ -- Vitro Diagnostics, Inc. (OTC Bulletin Board: VODG - news) announced today that it will present its research concerning new methods for growing human cells in culture at the Annual Meeting of the Endocrine Society to be held in Denver, Colorado on June 20-23, 2001. In announcing the decision to present this research, Dr. Jim Musick, President and CEO of Vitro, stated, ``The level of interest in this research has been such that we felt the benefits to the scientific research community merited presentation of our results at this point. It is our expectation that discussions of this work will increase exposure possibly leading to establishment of additional partnerships with Vitro. The general interest in the scientific community at large is demonstrated by the fact that NIH has awarded a research grant to Vitro for the study of cellular immortalization.'' Vitro's scientists were able to develop serum-free medium that promotes division of cultured pituitary cells, which is necessary for cellular immortalization. This research also demonstrated that cultured FSH-producing cells responded to physiological stimulation in an appropriate manner, showing that the cultures maintain characteristics of adult cells. The Company's product pipeline includes various forms of purified FSH and related products for use in the treatment of infertility. Fertility drugs in development include VITROPIN(TM), a highly purified form of human urinary FSH produced by the Company's patented method, VITROPIN-C(TM), custom FSH that reduces side effects of current products, VITROPIN-V(TM), a breakthrough FSH product produced from an immortalized cell line, and VITROJECT(TM), a novel drug injection device for administration of FSH and other drugs. The Company is also developing a platform technology to immortalize human cells. VITROCELL-X(TM) is the designation of a series of immortalized cell lines in which ``X'' represents the organ from which the cell line was derived, and each of which produces ``natural therapeutic'' products. For example, ``VITROCELL-PG(TM)'' is a cell line derived from the human pituitary gland that produces FSH. VITROCELL-X(TM) cell lines are produced by the Company's patent-pending method, VITROCELL-X(TM) CELL IMMORTALIZATION TECHNOLOGY, which uses controlled over-expression of specific genes to produce cellular immortalization. VITROCELL-X(TM) cell lines may also be used in cell therapeutic approaches to treat diseases resulting from cellular degeneration such as Type I diabetes and Alzheimer's disease. Certain statements contained herein, which are not historical, constitute ``forward looking statements'' within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements are identified by words such as ``intends,'' ``anticipates,'' ``believes,'' ``expects'' and ``hopes'' and include, without limitation, statements regarding the Company's plan of business operations, future financings and completion of certain transactions. Factors that could cause actual results to differ materially include, among others, the following: availability of necessary capital to develop its products, acceptability of the Company's product in the market place, approval of regulatory authorities, general economic conditions, competition and decisions of third parties over which the Company has no control. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward looking statements, whether as a result of new information, future events or otherwise. MAKE YOUR OPINION COUNT - Click Here tbutton.prnewswire.com SOURCE: Vitro Diagnostics, Inc. Email this story - Most-emailed articles - Most-viewed articles -------------------------------------------------------------------------------- More Quotes and News: Vitro Diagnostics Inc (OTC BB:VODG.OB - news) Related News Categories: medical/pharmaceutical -------------------------------------------------------------------------------- | ||||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |